115 related articles for article (PubMed ID: 27942524)
1. CK1δ: a pharmacologically tractable Achilles' heel of Wnt-driven cancers?
Cheong JK; Virshup DM
Ann Transl Med; 2016 Nov; 4(21):433. PubMed ID: 27942524
[TBL] [Abstract][Full Text] [Related]
2. The CK1δ/ϵ-Tip60 Axis Enhances Wnt/β-Catenin Signaling
Ning J; Sun Q; Su Z; Tan L; Tang Y; Sayed S; Li H; Xue VW; Liu S; Chen X; Lu D
Front Oncol; 2022; 12():844477. PubMed ID: 35494070
[TBL] [Abstract][Full Text] [Related]
3. Zebrafish as model system for the biological characterization of CK1 inhibitors.
Meier L; Gahr BM; Roth A; Gihring A; Kirschner S; Woitaske-Proske C; Baier J; Peifer C; Just S; Knippschild U
Front Pharmacol; 2023; 14():1245246. PubMed ID: 37753113
[No Abstract] [Full Text] [Related]
4. Therapeutic targeting of casein kinase 1δ in breast cancer.
Rosenberg LH; Lafitte M; Quereda V; Grant W; Chen W; Bibian M; Noguchi Y; Fallahi M; Yang C; Chang JC; Roush WR; Cleveland JL; Duckett DR
Sci Transl Med; 2015 Dec; 7(318):318ra202. PubMed ID: 26676609
[TBL] [Abstract][Full Text] [Related]
5. Casein kinase 1α has a non-redundant and dominant role within the CK1 family in melanoma progression.
Sinnberg T; Wang J; Sauer B; Schittek B
BMC Cancer; 2016 Aug; 16():594. PubMed ID: 27488834
[TBL] [Abstract][Full Text] [Related]
6. CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.
Ianes C; Xu P; Werz N; Meng Z; Henne-Bruns D; Bischof J; Knippschild U
Amino Acids; 2016 Feb; 48(2):579-92. PubMed ID: 26464264
[TBL] [Abstract][Full Text] [Related]
7. Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.
Halekotte J; Witt L; Ianes C; Krüger M; Bührmann M; Rauh D; Pichlo C; Brunstein E; Luxenburger A; Baumann U; Knippschild U; Bischof J; Peifer C
Molecules; 2017 Mar; 22(4):. PubMed ID: 28338621
[TBL] [Abstract][Full Text] [Related]
8. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.
Prosperi JR; Goss KH
Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611
[TBL] [Abstract][Full Text] [Related]
9. Relationship between a point mutation S97C in CK1δ protein and its affect on ATP-binding affinity.
Kumar A; Rajendran V; Sethumadhavan R; Purohit R
J Biomol Struct Dyn; 2014; 32(3):394-405. PubMed ID: 23527964
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) δ/ε.
García-Reyes B; Witt L; Jansen B; Karasu E; Gehring T; Leban J; Henne-Bruns D; Pichlo C; Brunstein E; Baumann U; Wesseler F; Rathmer B; Schade D; Peifer C; Knippschild U
J Med Chem; 2018 May; 61(9):4087-4102. PubMed ID: 29630366
[TBL] [Abstract][Full Text] [Related]
11. Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis.
Keenan CR; Langenbach SY; Jativa F; Harris T; Li M; Chen Q; Xia Y; Gao B; Schuliga MJ; Jaffar J; Prodanovic D; Tu Y; Berhan A; Lee PVS; Westall GP; Stewart AG
Front Pharmacol; 2018; 9():738. PubMed ID: 30042678
[TBL] [Abstract][Full Text] [Related]
12. Newly Developed CK1-Specific Inhibitors Show Specifically Stronger Effects on CK1 Mutants and Colon Cancer Cell Lines.
Liu C; Witt L; Ianes C; Bischof J; Bammert MT; Baier J; Kirschner S; Henne-Bruns D; Xu P; Kornmann M; Peifer C; Knippschild U
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817920
[TBL] [Abstract][Full Text] [Related]
13. CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application.
Winkler BS; Oltmer F; Richter J; Bischof J; Xu P; Burster T; Leithäuser F; Knippschild U
Front Cell Dev Biol; 2015; 3():9. PubMed ID: 25750912
[TBL] [Abstract][Full Text] [Related]
14. Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate beta-catenin.
Bryja V; Schulte G; Arenas E
Cell Signal; 2007 Mar; 19(3):610-6. PubMed ID: 17027228
[TBL] [Abstract][Full Text] [Related]
15. New potential peptide therapeutics perturbing CK1δ/α-tubulin interaction.
Krüger M; Kalbacher H; Kastritis PL; Bischof J; Barth H; Henne-Bruns D; Vorgias C; Sarno S; Pinna LA; Knippschild U
Cancer Lett; 2016 Jun; 375(2):375-383. PubMed ID: 26996302
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy.
Dzobo K; Thomford NE; Senthebane DA
OMICS; 2019 Nov; 23(11):517-538. PubMed ID: 31613700
[TBL] [Abstract][Full Text] [Related]
17. Wnt-β-catenin Signaling Pathway, the Achilles' Heels of Cancer Multidrug Resistance.
Ghandadi M; Valadan R; Mohammadi H; Akhtari J; Khodashenas S; Ashari S
Curr Pharm Des; 2019; 25(39):4192-4207. PubMed ID: 31721699
[TBL] [Abstract][Full Text] [Related]
18. Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.
Hwang SY; Deng X; Byun S; Lee C; Lee SJ; Suh H; Zhang J; Kang Q; Zhang T; Westover KD; Mandinova A; Lee SW
Cell Rep; 2016 Jun; 16(1):28-36. PubMed ID: 27320923
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C ζ is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines.
Luna-Ulloa LB; Hernández-Maqueda JG; Santoyo-Ramos P; Castañeda-Patlán MC; Robles-Flores M
Carcinogenesis; 2011 Nov; 32(11):1615-24. PubMed ID: 21859831
[TBL] [Abstract][Full Text] [Related]
20. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
